Finance

Lists
2196:HKG
Shanghai Fosun Pharmaceutical (Group) Ord Shs H
HK$17,15
-0,41%
(-0,070) 1D
15 Okt., 16:08:33 GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 2196...
Open
HK$17,13
High
HK$17,41
Low
HK$17,01
Mkt. cap
66,28 mjd
Avg. vol.
3,68 m
Volume
1,76 m
Dividend
2,62%
Quarterly dividend
HK$0,11
Ex-dividend date
27 Jul. 2026
P/E ratio
11,36
52-wk high
HK$24,84
52-wk low
HK$14,90
EPS
HK$1,51
Shares outstanding
551,94 m
No. of employees
41 k
Open
HK$17,13
High
HK$17,41
Low
HK$17,01
Mkt. cap
66,28 mjd
Avg. vol.
3,68 m
Volume
1,76 m
Dividend
2,62%
Quarterly dividend
HK$0,11
Ex-dividend date
27 Jul. 2026
P/E ratio
11,36
52-wk high
HK$24,84
52-wk low
HK$14,90
EPS
HK$1,51
Shares outstanding
551,94 m
No. of employees
41 k
News stories
From web sources and news partners
Profile
Shanghai Fosun Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company. It is mostly owned by Fosun International. As of 2018, the A shares of the company is a constituent of SSE 180 Index as well as its sub-index SSE MidCap Index. The company was ranked 1,840th in 2020 edition of the Forbes Global 2000, a list of top listed companies of the world. Wikipedia
About Shanghai Fosun Pharmaceutical (Group) Ord Shs H
CEOLiu Yi | Wen Deyong
Employees40,7 k
Founded1994
Headquarters-
SectorPharmaceutical industry
Last report
25 Aug. 2026
Fiscal period
Q2 2026
- / -
Revenue / Est. (CNY)
10,37 mjd / 10,66 mjd
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
9,88 mjd
12,27 mjd
10,07 mjd
10,37 mjd
Cost of goods sold
5,08 mjd
5,65 mjd
5,07 mjd
5,23 mjd
Cost of revenue
5,08 mjd
5,65 mjd
5,07 mjd
5,23 mjd
Research and development expenses
1,01 mjd
1,28 mjd
896,79 m
1,19 mjd
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,10 mjd
4,44 mjd
3,27 mjd
3,35 mjd
Operating expense
4,04 mjd
5,92 mjd
4,19 mjd
4,63 mjd
Total operating expenses
9,12 mjd
11,57 mjd
9,26 mjd
9,86 mjd
Operating income
758,38 m
699,05 m
813,78 m
505,27 m
Other non operating income
-116,85 m
107,33 m
2,03 m
-13,28 m
EBT including unusual items
1,12 mjd
1,27 mjd
1,36 mjd
1,23 mjd
EBT excluding unusual items
1,49 mjd
1,10 mjd
1,21 mjd
1,07 mjd
Income tax expense
162,98 m
82,80 m
277,92 m
159,73 m
Effective tax rate
14,57%
6,50%
20,47%
13,00%
Other operating expenses
-92,19 m
117,57 m
19,04 m
74,01 m
Net income
821,33 m
847,27 m
870,83 m
850,64 m
Net profit margin
8,31%
6,91%
8,64%
8,20%
Earnings per share
-
-
-
-
Interest and investment income
1,05 mjd
732,13 m
689,67 m
938,86 m
Interest expense
-321,25 m
-291,32 m
-296,51 m
-310,88 m
Net interest expenses
727,28 m
440,80 m
393,16 m
627,98 m
Depreciation and amortization charges
-
-
-
-
EBITDA
1,39 mjd
1,47 mjd
1,59 mjd
1,24 mjd
Gain or loss from assets sale
2,12 m
-69,35 m
-
-195,23 k
AI content may include mistakes. Learn more
Google-programme